The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children

Katriina Viinikainen1, Kai Eriksson, Anne Mönkkönen

  • 1Kuopio Epilepsy Center, Department of Neurology, Kuopio University Hospital and University of Kuopio, POB 1777, 70211, Kuopio, Finland. hkviinik@hytti.uku.fi

Epilepsy & Behavior : E&B
|October 20, 2006
PubMed

Insights

Children exposed to valproate during pregnancy showed increased risks for neurological and behavioral issues, requiring more educational support compared to controls. Further research is needed to confirm these findings.

Area of Science:

  • Neuroscience
  • Developmental Pediatrics
  • Clinical Neurology

Background:

  • Prenatal exposure to antiepileptic drugs (AEDs) can impact child neurodevelopment.
  • Valproate and carbamazepine are commonly used AEDs with potential teratogenic effects.

Purpose of the Study:

  • To evaluate neurological functioning, behavior, and educational needs in children exposed prenatally to valproate monotherapy.
  • To compare outcomes with age- and gender-matched controls exposed to carbamazepine and unexposed children.

Main Methods:

  • Population-based cohort study identifying children exposed to valproate (N=13) from a pregnancy registry (1989-2000).
  • Clinical neurological and neuropsychological assessments were performed.
  • Behavioral problems were assessed using the Conners' Teacher Rating Scale (CTRS).

Main Results:

  • Children exposed to valproate had significantly higher rates of requiring educational support (62%) compared to carbamazepine-exposed (15%) and nonexposed (15%) groups (P=0.022).
  • Minor dysmorphic features were more common in the valproate-exposed group (62%).
  • Valproate-exposed children exhibited more behavioral problems on the CTRS.

Conclusions:

  • Prenatal valproate exposure was associated with a higher incidence of cognitive, neurological, and behavioral problems in children.
  • These findings highlight potential neurodevelopmental risks associated with in utero valproate exposure.
  • Larger prospective studies are recommended to validate these observations due to confounding factors.

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...